Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vertex Pharmaceuticals Inc VRTX

Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.


NDAQ:VRTX - Post by User

Vertex Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Dec 19, 2024 6:15pm
38 Views
Post# 36371229

Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securiti

Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securiti
Just In: $VRTX Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the FirmBOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Block &amp; Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) for potential securities law violations. Investors who have lost money in their Vertex Pharmaceuticals Inc. investment should contact the firm to learn more about how they...VRTX - Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities